Catalent Inc
Change company Symbol lookup
Select an option...
CTLT Catalent Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
BWG BrandywineGLOBAL ? Global Income Opportunities Fund
BPYPO Brookfield Property Partners LP
HLAHU Hamilton Lane Alliance Holdings I Inc
GUERF Guerbet SA
BTCM BIT Mining Ltd
ATHE Alterity Therapeutics Ltd
Go

Health Care : Pharmaceuticals | Mid Cap Blend
Company profile

Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.

Postmarket

Last Trade
Delayed
$52.75
0.52 (1.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$52.23
Day's Change
2.10 (4.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.44
Day's Low
50.35
Volume
(Above Average)
Volume:
4,307,377

10-day average volume:
3,817,290
4,307,377

Carnival stock rallies after price target doubled at UBS

1:19 pm ET November 14, 2022 (MarketWatch)
Print

Shares of Carnival Corp. sailed 2.1% higher in afternoon trading Monday, after UBS analyst Robin Farley doubled his price target on the cruise operator, suggesting a further 51% upside is possible. Farley reiterated the buy rating he's had on Carnival while raising his stock price target to $16 from $8. Farley also raised his stock price targets for rivals Royal Caribbean Group to $76 from $56 and Norwegian Cruise Line Holdings Ltd. to $24 from $15. "We are raising estimates due to stronger demand since the lifting of COVID restrictions in the last 8 weeks, which has led to significantly higher booking volumes," Farley wrote in a note to clients. Meanwhile, Carnival's stock has significantly underperformed its peers over the past three months, falling 1.5% while Royal's stock soared 36.2% and Norwegian shares rallied 26.6%. In comparison, the S&P 500 fell 6.6% over the same time.

-Tomi Kilgore

	

(END) Dow Jones Newswires

November 14, 2022 13:19 ET (18:19 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.